The use of immune complex vaccines to enhance antibody responses against neutralizing epitopes on HIV-1 envelope gp120

Catarina E. Hioe, Maria Luisa Visciano, Rajnish Kumar, Jianping Liu, Ethan A. Mack, Rachel E. Simon, David Levy, Michael Tuen

Research output: Contribution to journalArticle

Abstract

The capacity of immune complexes to augment antibody (Ab) responses is well established. The enhancing effects of immune complexes have been attributed mainly to Fc-mediated adjuvant activity, while the ability of Abs to induce antigenic alterations of specific epitopes as a result of immune complex formation has been less well studied. Previously we have shown that the interaction of anti-CD4-binding site (CD4bs) Abs with HIV-1 gp120 induces conformation changes that lead to enhanced antigenicity and immunogenicity of neutralizing epitopes in the V3 loop. The present study shows that significant increases in the antigenicity of the V3 and C1 regions of gp120 were attained for several subtype B gp120s and a subtype C gp120 upon immune complex formation with the anti-CD4bs monoclonal Ab (mAb) 654-D. Such enhancement was observed with immune complexes made with other anti-CD4bs mAbs and anti-V2 mAbs, but not with anti-C2 mAbs, indicating this activity is determined by antigen specificity of the mAb that formed the immune complex. When immune complexes of gp120LAI/654-D and gp120JRFL/654-D were tested as immunogens in mice, serum Abs to gp120 and V3 were generated at significantly higher titers than those induced by the respective uncomplexed gp120s. Notably, the anti-V3 Ab responses had distinct fine specificities; gp120JRFL/654-D stimulated more cross-reactive anti-V3 Abs than gp120LAI/654-D. Neutralizing activities against viruses with heterologous envelope were also detected in sera of mice immunized with gp120JRFL/654-D, although the neutralization breadth was still limited. Overall this study shows the potential use of gp120/Ab complexes to augment the immunogenicity of HIV-1 envelope gp120, but further improvements are needed to elicit virus-neutralizing Ab responses with higher potency and breadth.

Original languageEnglish (US)
Pages (from-to)352-360
Number of pages9
JournalVaccine
Volume28
Issue number2
DOIs
StatePublished - Dec 11 2009

Fingerprint

antigen-antibody complex
Human immunodeficiency virus 1
Antigen-Antibody Complex
neutralization
epitopes
Antibody Formation
HIV-1
Epitopes
Vaccines
vaccines
antibodies
binding sites
Binding Sites
immune response
Viruses
antigens
viruses
mice
Neutralizing Antibodies
Serum

Keywords

  • Antibody response
  • HIV-1
  • Immune complex vaccine

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Hioe, C. E., Visciano, M. L., Kumar, R., Liu, J., Mack, E. A., Simon, R. E., ... Tuen, M. (2009). The use of immune complex vaccines to enhance antibody responses against neutralizing epitopes on HIV-1 envelope gp120. Vaccine, 28(2), 352-360. https://doi.org/10.1016/j.vaccine.2009.10.040

The use of immune complex vaccines to enhance antibody responses against neutralizing epitopes on HIV-1 envelope gp120. / Hioe, Catarina E.; Visciano, Maria Luisa; Kumar, Rajnish; Liu, Jianping; Mack, Ethan A.; Simon, Rachel E.; Levy, David; Tuen, Michael.

In: Vaccine, Vol. 28, No. 2, 11.12.2009, p. 352-360.

Research output: Contribution to journalArticle

Hioe, Catarina E. ; Visciano, Maria Luisa ; Kumar, Rajnish ; Liu, Jianping ; Mack, Ethan A. ; Simon, Rachel E. ; Levy, David ; Tuen, Michael. / The use of immune complex vaccines to enhance antibody responses against neutralizing epitopes on HIV-1 envelope gp120. In: Vaccine. 2009 ; Vol. 28, No. 2. pp. 352-360.
@article{d905d16135f3489f84038562686f5c4a,
title = "The use of immune complex vaccines to enhance antibody responses against neutralizing epitopes on HIV-1 envelope gp120",
abstract = "The capacity of immune complexes to augment antibody (Ab) responses is well established. The enhancing effects of immune complexes have been attributed mainly to Fc-mediated adjuvant activity, while the ability of Abs to induce antigenic alterations of specific epitopes as a result of immune complex formation has been less well studied. Previously we have shown that the interaction of anti-CD4-binding site (CD4bs) Abs with HIV-1 gp120 induces conformation changes that lead to enhanced antigenicity and immunogenicity of neutralizing epitopes in the V3 loop. The present study shows that significant increases in the antigenicity of the V3 and C1 regions of gp120 were attained for several subtype B gp120s and a subtype C gp120 upon immune complex formation with the anti-CD4bs monoclonal Ab (mAb) 654-D. Such enhancement was observed with immune complexes made with other anti-CD4bs mAbs and anti-V2 mAbs, but not with anti-C2 mAbs, indicating this activity is determined by antigen specificity of the mAb that formed the immune complex. When immune complexes of gp120LAI/654-D and gp120JRFL/654-D were tested as immunogens in mice, serum Abs to gp120 and V3 were generated at significantly higher titers than those induced by the respective uncomplexed gp120s. Notably, the anti-V3 Ab responses had distinct fine specificities; gp120JRFL/654-D stimulated more cross-reactive anti-V3 Abs than gp120LAI/654-D. Neutralizing activities against viruses with heterologous envelope were also detected in sera of mice immunized with gp120JRFL/654-D, although the neutralization breadth was still limited. Overall this study shows the potential use of gp120/Ab complexes to augment the immunogenicity of HIV-1 envelope gp120, but further improvements are needed to elicit virus-neutralizing Ab responses with higher potency and breadth.",
keywords = "Antibody response, HIV-1, Immune complex vaccine",
author = "Hioe, {Catarina E.} and Visciano, {Maria Luisa} and Rajnish Kumar and Jianping Liu and Mack, {Ethan A.} and Simon, {Rachel E.} and David Levy and Michael Tuen",
year = "2009",
month = "12",
day = "11",
doi = "10.1016/j.vaccine.2009.10.040",
language = "English (US)",
volume = "28",
pages = "352--360",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - The use of immune complex vaccines to enhance antibody responses against neutralizing epitopes on HIV-1 envelope gp120

AU - Hioe, Catarina E.

AU - Visciano, Maria Luisa

AU - Kumar, Rajnish

AU - Liu, Jianping

AU - Mack, Ethan A.

AU - Simon, Rachel E.

AU - Levy, David

AU - Tuen, Michael

PY - 2009/12/11

Y1 - 2009/12/11

N2 - The capacity of immune complexes to augment antibody (Ab) responses is well established. The enhancing effects of immune complexes have been attributed mainly to Fc-mediated adjuvant activity, while the ability of Abs to induce antigenic alterations of specific epitopes as a result of immune complex formation has been less well studied. Previously we have shown that the interaction of anti-CD4-binding site (CD4bs) Abs with HIV-1 gp120 induces conformation changes that lead to enhanced antigenicity and immunogenicity of neutralizing epitopes in the V3 loop. The present study shows that significant increases in the antigenicity of the V3 and C1 regions of gp120 were attained for several subtype B gp120s and a subtype C gp120 upon immune complex formation with the anti-CD4bs monoclonal Ab (mAb) 654-D. Such enhancement was observed with immune complexes made with other anti-CD4bs mAbs and anti-V2 mAbs, but not with anti-C2 mAbs, indicating this activity is determined by antigen specificity of the mAb that formed the immune complex. When immune complexes of gp120LAI/654-D and gp120JRFL/654-D were tested as immunogens in mice, serum Abs to gp120 and V3 were generated at significantly higher titers than those induced by the respective uncomplexed gp120s. Notably, the anti-V3 Ab responses had distinct fine specificities; gp120JRFL/654-D stimulated more cross-reactive anti-V3 Abs than gp120LAI/654-D. Neutralizing activities against viruses with heterologous envelope were also detected in sera of mice immunized with gp120JRFL/654-D, although the neutralization breadth was still limited. Overall this study shows the potential use of gp120/Ab complexes to augment the immunogenicity of HIV-1 envelope gp120, but further improvements are needed to elicit virus-neutralizing Ab responses with higher potency and breadth.

AB - The capacity of immune complexes to augment antibody (Ab) responses is well established. The enhancing effects of immune complexes have been attributed mainly to Fc-mediated adjuvant activity, while the ability of Abs to induce antigenic alterations of specific epitopes as a result of immune complex formation has been less well studied. Previously we have shown that the interaction of anti-CD4-binding site (CD4bs) Abs with HIV-1 gp120 induces conformation changes that lead to enhanced antigenicity and immunogenicity of neutralizing epitopes in the V3 loop. The present study shows that significant increases in the antigenicity of the V3 and C1 regions of gp120 were attained for several subtype B gp120s and a subtype C gp120 upon immune complex formation with the anti-CD4bs monoclonal Ab (mAb) 654-D. Such enhancement was observed with immune complexes made with other anti-CD4bs mAbs and anti-V2 mAbs, but not with anti-C2 mAbs, indicating this activity is determined by antigen specificity of the mAb that formed the immune complex. When immune complexes of gp120LAI/654-D and gp120JRFL/654-D were tested as immunogens in mice, serum Abs to gp120 and V3 were generated at significantly higher titers than those induced by the respective uncomplexed gp120s. Notably, the anti-V3 Ab responses had distinct fine specificities; gp120JRFL/654-D stimulated more cross-reactive anti-V3 Abs than gp120LAI/654-D. Neutralizing activities against viruses with heterologous envelope were also detected in sera of mice immunized with gp120JRFL/654-D, although the neutralization breadth was still limited. Overall this study shows the potential use of gp120/Ab complexes to augment the immunogenicity of HIV-1 envelope gp120, but further improvements are needed to elicit virus-neutralizing Ab responses with higher potency and breadth.

KW - Antibody response

KW - HIV-1

KW - Immune complex vaccine

UR - http://www.scopus.com/inward/record.url?scp=70649105392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70649105392&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.10.040

DO - 10.1016/j.vaccine.2009.10.040

M3 - Article

C2 - 19879224

AN - SCOPUS:70649105392

VL - 28

SP - 352

EP - 360

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 2

ER -